Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Biorxiv : the Preprint Server for Biology
|
January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLC
Hilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research
|
May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors
Hilal Ozakinci, Bina Desai, Denise Kalos, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2024
Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators
Bina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Biorxiv : the Preprint Server for Biology
|
June 12, 2026
Ploidy shapes gemcitabine response through altered potency and delayed cell death
Vural Tagal, Tao Li, Rikhil Kumar, et al.
Biorxiv : the Preprint Server for Biology
|
June 4, 2026
Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLC
Pragya Kumar, Menkara Henry, Julia Pelesko, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Research Square
|
May 2, 2025
Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers
Bina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Nature Communications
|
May 16, 2020
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
Robert Vander Velde, Nara Yoon, Viktoriya Marusyk, et al.
Nature Communications
|
July 26, 2023
Virtual alignment of pathology image series for multi-gigapixel whole slide images
Chandler D Gatenbee, Ann-Marie Baker, Sandhya Prabhakaran, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Biorxiv : the Preprint Server for Biology
|
January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLC
Hilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research
|
May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors
Hilal Ozakinci, Bina Desai, Denise Kalos, et al.
Biorxiv : the Preprint Server for Biology
|
May 7, 2024
Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators
Bina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Biorxiv : the Preprint Server for Biology
|
June 12, 2026
Ploidy shapes gemcitabine response through altered potency and delayed cell death
Vural Tagal, Tao Li, Rikhil Kumar, et al.
Biorxiv : the Preprint Server for Biology
|
June 4, 2026
Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLC
Pragya Kumar, Menkara Henry, Julia Pelesko, et al.
Biorxiv : the Preprint Server for Biology
|
September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Science Signaling
|
December 23, 2025
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i>-driven lung cancer by concurrent integrin and MET signaling
Qianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Research Square
|
May 2, 2025
Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancers
Bina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Nature Communications
|
May 16, 2020
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
Robert Vander Velde, Nara Yoon, Viktoriya Marusyk, et al.
Nature Communications
|
July 26, 2023
Virtual alignment of pathology image series for multi-gigapixel whole slide images
Chandler D Gatenbee, Ann-Marie Baker, Sandhya Prabhakaran, et al.
Page
of 8